FOXO4-DRI: preclinical evidence and human risks
FOXO4-DRI: the FOXO4-p53 mechanism, findings in mice and human tissues, an adverse pulmonary signal and registry checks. No protocol.
Read the analysisSupplements
Identify supplements that are really worth your money: independent analyses covering studied doses, side effects and limits of the evidence, without marketing jargon.
Recent features
Magnesium bisglycinate: review, evidence and limitations
Is bisglycinate better tolerated and useful for sleep? An evidence-based review, elemental doses, clinical evidence and a framework to help you decide before a course of supplementation.
Oxiracetam: cognitive evidence, risks and status
Oxiracetam, S-oxiracetam and memory: populations studied, recent trials, risks, French status and what an Orphanet entry means. No usage protocol.
Selank: evidence, risks and status in France
Selank and anxiety: heptapeptide identity, limited human trials, animal data, unknown risks and checks of French registries. No protocol.
5-Amino-1MQ: evidence, risks and status in France
A small molecule, not a peptide: cellular and animal evidence on 5-Amino-1MQ, human unknowns, and checks of French and European registries.
HMB: muscle benefits, studied doses and limitations
HMB or protein? Compare trials by age and training status, Ca-HMB doses, and two labels with their cost per serving.